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Introduction
In normal animals and subjects, glucose is filtered at the glomerulus of the kidney and almost completely reabsorbed by sodium-glucose cotransporters (SGLT) expressed in the proximal tubules. Two isoforms of SGLT with different affinity to glucose are localized at different positions in the proximal tubule: a low-affinity and high-capacity transporter (SGLT2) is expressed in the convoluted tubule and a high-affinity and low-capacity transporter (SGLT1) is expressed in the straight tubule (Turner and It has been reported that inhibiting SGLT increases urinary glucose excretion (UGE) and reduces blood glucose, which improves glycemic control in an insulin-independent manner (Rossetti et al., 1987; Oku et al., 2000) . Accordingly, several SGLT inhibitors are currently under clinical development for type II diabetes treatment (Abdul-Ghani et al., 2011; Kipnes, 2011). Considering that two isoforms of SGLT with different properties contribute to renal glucose reabsorption and that SGLT1 is expressed in not only the kidney but also the small intestine (Hediger and Rhoads, 1994), the inhibition potency to each transporter would be an important factor in efficacy and safety. Although both SGLT1 and SGLT2 in the kidney can be targets for type II diabetes treatment, most SGLT inhibitors being developed have high selectivity toward Inhibition study of AMG uptake using cells expressing rat and mouse SGLTs. In vitro inhibition studies using cells expressing rat SGLT1 (rSGLT1), rat SGLT2 (rSGLT2), mouse SGLT1 (mSGLT1), and mouse SGLT2 (mSGLT2) were performed by the method previously reported (Suzuki et al., 2012) , as follows. Rat and mouse SGLTs cDNA was amplified with total RNA isolated from the kidney or small intestine of a Wistar rat or a db/db mouse. PCR primers were designed from published sequences (GenBank accession number: NM001107229 (rSGLT1), NM022590 (rSGLT2), BC003845 (mSGLT1), AY033886
(mSGLT2)). E  T  #  2  0  3  1  2  5 1 1 using the equilibrium dialysis method. 100 mM potassium phosphate buffered solution (pH 7.4) was added to a receptor chamber, and rat serum containing a test compound (final concentration: 100 ng/ml) was added to a donor chamber. The equilibrium dialysis apparatus was incubated in a shaking bath for 24 h at 37°C. After incubation, buffer and serum samples were collected, and the test compound concentrations were measured using LC-MS/MS. The fraction unbound in serum (f u ) was calculated using the equation below:
where C buffer and C serum were test compound concentration in buffer and serum, respectively. PK-PD studies of SGLT inhibitors in rats. Under ether anesthesia, polyethylene cannulae were placed in the femoral artery and vein of each rat, and a silicon cannula was placed in the bladder. After surgery, the rats were housed in Bollman cages (Natsume Seisakusho Co., Ltd., Tokyo, Japan). The dosing solutions were administered as a bolus through the femoral venous cannula or by oral gavage. The composition of the dosing solution for each drug is summarized in of urine was initiated 1 h before administration and terminated 8 h after administration. The bladder was washed with 1 ml of saline in order to collect urine completely at each sampling point. The glucose concentrations in plasma and urine samples were determined using a Glucose CII-Test Wako kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The PK-PD data of phlorizin was cited from a previous report indomethacin. Run cycles of measurements were set at 10 min (tofogliflozin and BMS), 6 min (T-1095A), and 13 min (sergliflozin-A). The linear calibration curve for each compound using peak area was obtained in the range of 10-2,000 ng/ml for tofogliflozin, 1-1,000 ng/ml for BMS, 30-2,000 ng/ml for sergliflozin-A, and 3-300 ng/ml for T-1095A, with weighting 1/y.
Estimation of renal clearance and average plasma concentration. The renal glucose clearance
(CL R,Glc ) during each urine sampling period was estimated using the following equation:
where C U,Glc is the concentration of glucose in urine, V is the urine volume, and AUC Glc is the area under the time-plasma concentration curve for glucose during the corresponding urine-sampling period (τ). The average plasma concentrations of glucose (C Av,Glc ) and test compound (C Av,Drug ) were also estimated by the This article has not been copyedited and formatted. The final version may differ from this version. In order to express the renal glucose reabsorption and the inhibitory effect of an SGLT inhibitor, the following concepts were assumed in the model: 1) first, the filtered plasma glucose is reabsorbed by SGLT2, and then the remainder is reabsorbed by SGLT1; 2) the flow rate in the proximal tubule is the same as the glomerular filtration rate (GFR); 3) the glucose concentration in the proximal tubule is altered only by the reabsorption mediated by SGLTs; 4) the glucose reabsorption process mediated by SGLTs is expressed by a nonlinear parallel tube model; 5) the inhibitor concentration in the proximal tubule is the same as that in plasma and shows a constant value; and 6) an inhibitor competitively inhibits the glucose transport mediated by SGLTs. A schematic representation of the PK-PD model is shown in Fig. 2 . The glucose transport in the proximal tubule at time t is expressed by the following equations:
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where Eqs. 1 and 2 express the glucose transport at the compartments of SGLT2 and SGLT1, respectively.
C in2 (t) is the glucose concentration just after filtration at time t, which is equal to the glucose concentration in plasma at time t (C P,Glc (t)). C out2 (t) is the glucose concentration at the end of the SGLT2 compartment and is equal to C in1 (t), which is the concentration at the entrance of the SGLT1 compartment at time t . C out1 (t) is the concentration at the end of the SGLT1 compartment at time t. C (t) is the plasma concentration of an inhibitor at time t after administration. K i, SGLT1 and K i, SGLT2 are the inhibition constants of an inhibitor for SGLT1 and SGLT2, respectively. The plasma concentration-time profile of an inhibitor, C(t), is assumed to be expressed based on a 2-compartment model. Then the following equation was obtained: 
where Dose is the administration dose, V 1 is the distribution volume of the central compartment, k 12 and k 21 are the rate constants from central to peripheral and from peripheral to central compartment, respectively, k 10 is the elimination rate constant from the central compartment, and α and β are the elimination rate constants at α -and β -phase, respectively.
The renal glucose clearance at time t (CL R,Glc (t)) was estimated by the following equation:
This article has not been copyedited and formatted. The final version may differ from this version. 
The cumulative glucose amount excreted in urine at time t (Q U,Glc (t)) was estimated by the following equation:
Estimation of pharmacokinetic parameters. The plasma concentration-time profile of each test compound after intravenous administration to rat was analyzed based on the 2-compartment model using WinNonlin Ver. 5.0 software (Pharsight Co., Mountain View, CA, USA).
PK-PD analysis. The time course of cumulative glucose excreted after intravenous administration of an SGLT inhibitor was analyzed based on the PK-PD model using the following procedure. The C(t) was simulated based on the 2-compartment model using the PK parameters obtained from the present PK analysis. The C P,Glc (t) was calculated by linear interpolation between observed values. Next, the fixed values (K m, SGLT1 , K m, SGLT2 , V max, SGLT1 , V max, SGLT2 , and GFR) obtained from the previous study (Yamaguchi et al., 2011) and simulated values (C(t) and C P,Glc (t)) were substituted into Eqs. 1-4. Then the values for Q U, Glc (t) observed in the PK-PD study were fitted to Eq. 4 in order to estimate the parameters, rat K i, SGLT1 and rat K i, SGLT2 . Curve-fitting procedures were performed using a nonlinear least square regression program, MULTI Sensitivity analysis. In order to understand the relationship between selectivity toward SGLT2 and the effect on UGE, a simulation study was performed using the present PK-PD model. In the simulation, the PD parameters relating to renal glucose transport were used (Table 2) , and it was assumed that K i,SGLT2
of an SGLT inhibitor was 1 nM and that the selectivity toward SGLT2 was in the range of 1 to 1,000. In addition, no inhibition of SGLT1 (infinite selectivity toward SGLT2) was also assumed. CL R,Glc values were calculated under a static SGLT inhibitor concentration and at plasma glucose levels of 1, 2, or 3 mg/ml. This article has not been copyedited and formatted. The final version may differ from this version. 15 nM). Tofogliflozin, BMS, and sergliflozin-A showed relatively high selectivity toward SGLT2 (rat: more than 170, mouse: more than 150) while T-1095A and phlorizin showed less selectivity (rat: less than 20, mouse: less than 19). The rank orders of IC 50 values for both SGLT1 and SGLT2 and of selectivity toward SGLT2 in rat were the same as those in mouse.
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CL R,Glc after administration of SGLT inhibitors. The relationship between CL R,Glc and C Av,Drug after administration of test compounds is plotted in Fig. 3 . Tofogliflozin, BMS, and sergliflozin were administered intravenously and orally, and the plots obtained from both administration routes are overlapped for each compound (Figs. 3a-3c ). The regression curve was estimated for each test compound using the plots of CL R,Glc values that were in the range of 50 to 400 ml/h/kg, and using the following equation:
The slopes of the regression curves for less selective SGLT2 inhibitors (T-1095A and phlorizin) were This article has not been copyedited and formatted. The final version may differ from this version. steeper than those for highly selective ones (tofogliflozin, BMS, and sergliflozin-A).
PK-PD analysis of SGLT inhibitors for renal glucose transport. The effect of an SGLT inhibitor on UGE after intravenous administration was analyzed based on the PK-PD model. The plasma concentration-time profile of each compound was suitably expressed using the 2-compartment model (Fig.   4) , and the estimated parameters were summarized in Table 4 . Using the fixed PD parameters relating to glucose transport (Table 2) (Yamaguchi et al., 2011) and simulated plasma concentrations of compound and glucose, the curve-fitting of cumulative UGE for each compound was performed based on the PK-PD model. The cumulative UGE of each test compound was suitably described by the present model (Fig. 4) ;
and K i,SGLT2 were estimated ( Table 3) . (Fig. 5b) .
Sensitivity analysis. In order to understand how the selectivity toward SGLT2 of an SGLT inhibitor affects its inhibition of renal glucose reabsorption, a sensitivity analysis was performed: the fractional excretion of filtered glucose (FE) was simulated assuming 1 nM of K i, SGLT2 value, different selectivity toward SGLT2, and several plasma glucose levels. In the case of euglycemic condition (1 mg/ml), the threshold inhibitor concentration which causes more than 0.1% of FE was 3.0 nM when selectivity was 1, and 6.5-8.0 nM when selectivity was in the range of 10 to infinity (Fig. 6a) . The threshold concentration increased as selectivity toward SGLT2 increased. In the case of hyperglycemic condition (2 mg/ml), the threshold concentrations for different levels of selectivity toward SGLT2 were comparable, with values in the range of 1.5 to 2.0 nM (Fig. 6b) .
Under euglycemic condition, FE values showed a broad range between the different levels of selectivity toward SGLT2, with high selectivity causing a low FE value; FE value at a drug concentration of 1,000 nM was 96.0% when selectivity was 1, and was 53.8% when selectivity was infinity (Fig. 6a) . Under hyperglycemic condition, on the other hand, the difference in FE between compounds with different levels of selectivity was slight; FE value at a drug concentration of 1,000 nM and at plasma glucose of 2 mg/ml was 96.2% when selectivity was 1, and was 76.0% when selectivity was infinity (Fig. 6b) ; and FE value at a drug concentration of 1,000 nM at plasma glucose of 3 mg/ml was 96.3% when selectivity was 1, and This article has not been copyedited and formatted. The final version may differ from this version. was 83.6% when selectivity was infinity (Fig. 6c) . The difference in FE got smaller as plasma glucose concentration increased.
Discussion
In the present study, a PK-PD analysis was performed based on a nonlinear parallel tube model, in which different properties in glucose transport between SGLT1 and SGLT2 were considered, in order to estimate in vivo K i values and selectivity toward SGLT2 of SGLT inhibitors. The present PK-PD model was applied to SGLT inhibitors with different in vitro IC 50 values and selectivity toward SGLT2 and could suitably express their time courses of UGE after administration (Fig. 4) . We previously reported that the PK-PD model could express the plasma glucose concentration-dependent renal glucose excretion and the inhibitory effect of a less selective inhibitor, phlorizin, on renal glucose reabsorption in normal rat (Yamaguchi et al., 2011) . In the present study, it was found that this model could be used to analyze the effect of other inhibitors including highly selective SGLT2 inhibitors such as tofogliflozin. The in vivo K i × f u values for SGLT1 and SGLT2 estimated using the present PK-PD model were comparable to the in vitro values (Fig. 5a) . Moreover, the in vivo selectivity toward SGLT2 showed a good correlation with that in vitro (Fig. 5b) . These results suggest that in vitro inhibition potency is reflected in vivo. Although plasma and proximal tubular drug concentrations were assumed to be equal in the analysis, the assumption would not reflect the actual in vivo situation because of renal secretion or reabsorption of a drug; for example, when renal reabsorption of a drug occurs, the estimated inhibition constant based on plasma drug concentration.
When designing a potent SGLT2 inhibitor with specificity for a target organ, not only inhibition potency to SGLT2 but also selectivity toward SGLT2 are important indexes at the preclinical drug discovery stage. However, little is known of how the selectivity toward SGLT2 of a compound affects its inhibition potency for renal glucose reabsorption. In the present study, CL R,Glc was used to express the inhibitory effect of SGLT inhibitors on renal glucose reabsorption in order to evaluate the in vivo inhibition potency. As shown in potency of a compound for renal glucose reabsorption. For a further understanding of the relationship between selectivity toward SGLT2 and inhibition potency for renal glucose reabsorption, a simulation study based on the PK-PD model was performed assuming several levels of selectivity toward SGLT2 under euglycemic and hyperglycemic conditions. The simulation results indicated that the inhibition potency of a highly selective SGLT2 inhibitor for renal glucose reabsorption was milder than that of a less selective one under euglycemic condition (Fig. 6a) . CL R, Glc observed in the present study ( Fig. 3) hand, the simulation results indicated that the inhibition potency of a highly selective SGLT2 inhibitor got greater as plasma glucose increased, and that the difference in FE between inhibitors with different selectivity toward SGLT2 was slight under hyperglycemic condition (Figs. 6b and 6c) . Nagata el al.
(2012) reported that, in rats, a highly selective SGLT2 inhibitor, tofogliflozin, and a less selective one, phlorizin, showed 60% and 70% FE, respectively, at the unbound plasma concentrations (tofogliflozin: 196 nM, phlorizin: 1123 nM) under hyperglycemic conditions (300 mg/dl) but showed 20% and 60% FE, respectively, at the same concentrations under euglycemic conditions (100 mg/dl). Moreover, it was reported that the maximum renal glucose clearance induced by a highly selective SGLT2 inhibitor was comparable with that by a less selective inhibitor in db/db mice (Yamaguchi et al., 2012). These facts suggest the validity of the simulation under hyperglycemic conditions. This article has not been copyedited and formatted. The final version may differ from this version. It was reported that a highly selective SGLT2 inhibitor, dapagliflozin, showed a low risk of hypoglycemia in clinical trials in that the overall incidence of major hypoglycemic events did not exceed 1% and was not significantly increased by dapagliflozin treatment; however, the risk of mild hypoglycemic events was more frequent with dapagliflozin than the placebo (Musso et al., 2012) . Most SGLT inhibitors in clinical development have high selectivity toward SGLT2; thus, the risk of hypoglycemia for a less selective SGLT inhibitor is not clear but may be higher than for a highly selective one because a less selective one can inhibit not only SGLT2 in the kidney but also SGLT1 in both the kidney and the small intestine. Even if we focus on the action of an SGLT inhibitor only in the kidney, as shown in the simulation study, highly selective SGLT2 inhibition exhibiting mild FE under euglycemic condition ( Fig.   6a ) and great FE equal to a less selective one under hyperglycemic condition (Figs. 6b and 6c ) would be a preferable characteristic for treating type II diabetes without incurring hypoglycemia because there would be no necessity to reduce blood glucose under euglycemic conditions for the treatment.
Although SGLT1 has been considered to make a minor contribution to renal glucose reabsorption contribution of SGLT1 to renal glucose reabsorption is an interesting issue for understanding the efficacy of an SGLT inhibitor. The present PK-PD model could suitably express the phenomenon described above by assuming infinite selectivity toward SGLT2 of an SGLT inhibitor, i.e., no inhibition potency to SGLT1, under euglycemic condition as follows: the complete inhibition of SGLT2 caused 55% of FE, and the rest was reabsorbed by SGLT1 (Fig. 6a) . This means that SGLT1 has transport capacity to reabsorb 45% of the filtered glucose under euglycemic condition when SGLT2 does not contribute to glucose reabsorption.
Moreover, the simulation assuming infinite selectivity toward SGLT2 showed that FE was higher under hyperglycemic than euglycemic condition (Figs. 6b and 6c) . According to the assumptions of the PK-PD model, the difference in FE between eu-and hyperglycemic conditions can be simply explained as follows: However, the lack of SGLT1 function is likely to limit its usefulness. The present PK-PD model would be suitable for a comprehensive understanding of renal glucose movement and the inhibitory effect of an SGLT inhibitor on renal glucose reabsorption because the model includes the differences between SGLT1
and SGLT2 not only in affinity and transport capacity for glucose but also in inhibition potency of a compound.
In conclusion, the present PK-PD model enabled us to analyze UGE induced by SGLT inhibitors with a wide range of selectivity toward SGLT2, and the estimated in vivo K i × f u values for both SGLT1 and SGLT2 were comparable to the in vitro data. Thus, the model would be useful for predicting UGE caused 
